Ann: New case of SCENESSE efficacy in vitiligo presented at AAD, page-9

Yes good results from Clinuvel showing again how effective their already FDA approved drug is in a blockbuster indication (~1% of the planets population). Share price action also again showing how short sellers are super vigilant with CUV and knock down the price regardless of profits, results etc and a share buyback to protect shareholder interests is essential. Buying back shares here is a great investment for CUV, only one analyst has priced in Vitiligo (and lets be honest we know it works and the likelihood of approval is sky high IMO) and that analyst has a PT near $50. Other analysts just on EPP have the price in the $20s so Clinuvel should be taking this opportunity to make some use of the enormous cash pile they are sitting on. Even the robots at the ASX could see how impressive these Vitiligo results are they marked it as a 'price sensitive' announcement which they often decline to do.

All IMO DYOR